Colloidal bismuth subcitrate in peptic ulcer--a review

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Peptic ulcers, including duodenal ulcers (DU) and gastric ulcers (GU), represent a significant gastrointestinal condition.
• Current treatments often involve H2-receptor blockers, but alternative or superior therapeutic options are continually sought.

Purpose of the Study:

• To evaluate the efficacy of colloidal bismuth subcitrate (CBS) in healing DU and GU.
• To compare the healing rates and relapse-free outcomes of CBS against established treatments like cimetidine and ranitidine.

Main Methods:

• Clinical trials comparing CBS treatment with cimetidine and ranitidine for DU and GU.
• Assessment of ulcer healing rates after 4 weeks of treatment.
• Long-term follow-up (1 year) to determine relapse-free rates.

Main Results:

• CBS achieved an average healing rate of 78% for DU versus 63% for cimetidine.
• Direct comparison showed CBS at 84% healing versus ranitidine at 78% for DU.
• CBS demonstrated a 68% healing rate for GU compared to 54% for cimetidine.
• Significantly higher relapse-free rates were observed with CBS after 1 year compared to H2-receptor blockers.

Conclusions:

• Colloidal bismuth subcitrate (CBS) is a highly effective treatment for both duodenal and gastric ulcers.
• CBS exhibits superior healing efficacy and better long-term relapse prevention than cimetidine and ranitidine.
• The mechanism of action, involving adherence to ulcer craters and inhibition of pepsin, contributes to its therapeutic success.